[go: up one dir, main page]

HUS2400033I1 - A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy - Google Patents

A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy

Info

Publication number
HUS2400033I1
HUS2400033I1 HUS2400033C HUS2400033C HUS2400033I1 HU S2400033 I1 HUS2400033 I1 HU S2400033I1 HU S2400033 C HUS2400033 C HU S2400033C HU S2400033 C HUS2400033 C HU S2400033C HU S2400033 I1 HUS2400033 I1 HU S2400033I1
Authority
HU
Hungary
Prior art keywords
biphenylsulfonamide
endothelin
angiotensin
iga
receptor antagonist
Prior art date
Application number
HUS2400033C
Other languages
Hungarian (hu)
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42828649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS2400033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of HUS2400033I1 publication Critical patent/HUS2400033I1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
HUS2400033C 2009-03-31 2024-09-30 A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy HUS2400033I1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16541909P 2009-03-31 2009-03-31
US16544709P 2009-03-31 2009-03-31
EP17157697.8A EP3222277B1 (en) 2009-03-31 2010-03-29 A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy

Publications (1)

Publication Number Publication Date
HUS2400033I1 true HUS2400033I1 (en) 2024-10-28

Family

ID=42828649

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE17157697A HUE049450T2 (en) 2009-03-31 2010-03-29 Endothelin and angiotensin II receptor antagonist for the treatment of biphenylsulfonamide glomerulosclerosis and IgA-induced nephropathy
HUE14155459A HUE033494T2 (en) 2009-03-31 2010-03-29 A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
HUS2400033C HUS2400033I1 (en) 2009-03-31 2024-09-30 A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE17157697A HUE049450T2 (en) 2009-03-31 2010-03-29 Endothelin and angiotensin II receptor antagonist for the treatment of biphenylsulfonamide glomerulosclerosis and IgA-induced nephropathy
HUE14155459A HUE033494T2 (en) 2009-03-31 2010-03-29 A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis

Country Status (18)

Country Link
US (4) US20140142149A1 (en)
EP (4) EP3708163A1 (en)
JP (3) JP2012522058A (en)
CN (2) CN104107176A (en)
CY (2) CY1119232T1 (en)
DK (2) DK3222277T3 (en)
ES (2) ES2811342T3 (en)
FI (1) FIC20240031I1 (en)
FR (1) FR24C1038I1 (en)
HR (2) HRP20171197T1 (en)
HU (3) HUE049450T2 (en)
LT (3) LT2732818T (en)
NL (1) NL301291I2 (en)
PL (2) PL3222277T3 (en)
PT (2) PT3222277T (en)
SI (2) SI2732818T1 (en)
SM (2) SMT202000269T1 (en)
WO (1) WO2010114801A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011280969A1 (en) 2010-07-23 2013-02-07 Trustees Of Boston University Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
AR083417A1 (en) * 2010-10-14 2013-02-21 Novartis Ag PHARMACEUTICAL COMPOSITIONS CONTAINING AN INHIBITOR DGAT1
US20130022551A1 (en) * 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
EP3763374A1 (en) * 2011-10-17 2021-01-13 Lexicon Pharmaceuticals, Inc. Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
ES2790358T3 (en) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
EP2797416B1 (en) 2011-12-28 2017-08-09 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013149258A2 (en) 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions and methods for treating or preventing metabolic syndrome disorders
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105246477A (en) 2013-03-15 2016-01-13 全球血液疗法股份有限公司 Compounds and their use for regulating hemoglobin
PE20161035A1 (en) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc COMPOUNDS AND USES OF THESE FOR THE MODULATION OF HEMOGLOBIN
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102293060B1 (en) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
PE20160194A1 (en) 2013-06-13 2016-04-20 Akebia Therapeutics Inc COMPOSITIONS AND METHODS TO TREAT ANEMIA
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
CN105960397B (en) * 2014-02-05 2020-09-04 默沙东公司 CGRP - tablet formulation of active compound
HUE053706T2 (en) 2014-02-07 2021-07-28 Global Blood Therapeutics Inc Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN104367576A (en) * 2014-10-24 2015-02-25 南方医科大学南方医院 Use of compound ICG-001 in preparation of medicine for treating hypertension
US10202457B2 (en) 2015-08-24 2019-02-12 Trustees Of Boston University Anti-DEspR monoclonal antibody targeted therapy and imaging for cancer and stroke
WO2017096230A1 (en) 2015-12-04 2017-06-08 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TW202332423A (en) * 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US20190262317A1 (en) * 2016-10-13 2019-08-29 Retrophin, Inc. Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
EP3615002A4 (en) * 2017-04-25 2021-01-06 Proteus Digital Health, Inc. LISINOPRIL COMPOSITIONS WITH A TAKE-UP EVENT MARKER
EP3684400A4 (en) 2017-09-18 2021-06-16 Trustees of Boston University Methods for treating netosis and neutrophil activation
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US10953107B2 (en) 2018-06-15 2021-03-23 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
KR20210081338A (en) 2018-10-04 2021-07-01 트래버르 테라퓨틱스, 인코포레이티드 Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
EP3897834A1 (en) * 2018-12-21 2021-10-27 Travere Therapeutics, Inc. Amorphous sparsentan compositions
WO2020136441A1 (en) * 2018-12-28 2020-07-02 Gnt Pharma Co., Ltd. Compositions and methods for treating neurodegenerative disorders
WO2020166710A1 (en) 2019-02-15 2020-08-20 国立大学法人東北大学 1, 3-dioxolan derivative
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited TREATMENT OF MIGRAINE
WO2022081792A1 (en) 2020-10-15 2022-04-21 Trustees Of Boston University Antibody therapies and methods for treating coronavirus infection
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
JP7458085B2 (en) * 2021-07-28 2024-03-29 株式会社三協 Disintegrant for tablets and tablets using the same
CN117836294A (en) 2021-08-26 2024-04-05 上海翰森生物医药科技有限公司 Aromatic ring-containing biological antagonist, preparation method and application thereof
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
AR128112A1 (en) * 2021-12-28 2024-03-27 Alchemedicine Inc COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
CN115636799A (en) * 2022-11-04 2023-01-24 苏州莱安医药化学技术有限公司 Preparation method of double-effect endothelin-angiotensin receptor antagonist
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
WO2024249509A1 (en) 2023-05-31 2024-12-05 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
IT202300018276A1 (en) * 2023-09-06 2025-03-06 Procos Spa PROCESS FOR THE PREPARATION OF SPARSENTAN
WO2025064688A1 (en) 2023-09-20 2025-03-27 Travere Therapeutics, Inc. Sparsentan for treating immunoglobulin a nephropathy (igan)
WO2025094214A1 (en) * 2023-11-02 2025-05-08 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl) benzenesulfonamide and its intermediates thereof
WO2025149789A1 (en) * 2024-01-09 2025-07-17 Procos S.P.A. Process for the preparation of sparsentan
CN120289447A (en) * 2025-06-11 2025-07-11 成都臻拓医药科技有限公司 A crystal form of sparsentan, preparation method thereof, and pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US793898A (en) 1905-03-01 1905-07-04 William Mcintosh Locomotive-tender frame.
US1395298A (en) 1919-11-20 1921-11-01 Walter H Richman Container
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
WO2000001389A1 (en) * 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
AU760174B2 (en) 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US7390824B1 (en) 1999-09-07 2008-06-24 Bristol-Myers Squibb Company Method for treating diabetes employing an aP2 inhibitor and combination
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ATE339417T1 (en) * 1999-12-15 2006-10-15 Bristol Myers Squibb Co BIPHENYL - SULFONAMIDE AS DUAL ANGIOTENSIN - ENDOTHELIN - RECEPTOR - ANTAGONISTS

Also Published As

Publication number Publication date
ES2811342T3 (en) 2021-03-11
ES2636087T3 (en) 2017-10-05
FIC20240031I1 (en) 2024-10-01
US20170354646A1 (en) 2017-12-14
LTPA2024527I1 (en) 2024-10-25
SMT202000269T1 (en) 2020-07-08
CN104107176A (en) 2014-10-22
DK3222277T3 (en) 2020-05-11
EP2413930A4 (en) 2012-09-26
US20180344705A1 (en) 2018-12-06
HRP20200665T1 (en) 2020-08-21
SMT201700416T1 (en) 2017-11-15
EP3222277A1 (en) 2017-09-27
PL2732818T3 (en) 2017-12-29
LT3222277T (en) 2020-05-11
NL301291I2 (en) 2024-10-30
CN102421434A (en) 2012-04-18
SI3222277T1 (en) 2021-02-26
SI2732818T1 (en) 2017-12-29
PL3222277T3 (en) 2020-08-24
PT3222277T (en) 2020-07-08
EP2413930A1 (en) 2012-02-08
FR24C1038I1 (en) 2024-12-06
JP2017008081A (en) 2017-01-12
EP2732818B1 (en) 2017-05-03
LT2732818T (en) 2017-09-25
US9993461B2 (en) 2018-06-12
DK2732818T3 (en) 2017-08-14
HUE049450T2 (en) 2020-09-28
CY1119232T1 (en) 2018-02-14
US20150164865A1 (en) 2015-06-18
EP3222277B1 (en) 2020-02-26
HRP20171197T1 (en) 2017-10-20
EP2732818A1 (en) 2014-05-21
EP3708163A1 (en) 2020-09-16
HUE033494T2 (en) 2017-12-28
JP2012522058A (en) 2012-09-20
JP2015052001A (en) 2015-03-19
WO2010114801A1 (en) 2010-10-07
HK1244687A1 (en) 2018-08-17
PT2732818T (en) 2017-08-07
CY1123017T1 (en) 2021-10-29
US9662312B2 (en) 2017-05-30
US20140142149A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
HUS2400033I1 (en) A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy
AP3170A (en) New CCR2 receptor antagonists and uses thereof
ZA201202029B (en) Androgen receptor antagonists and uses thereof
IL220151A0 (en) Neutralizing prolactin receptor antiobodies and their therapeutic use
IL216536A0 (en) A collection and methods for its use
SG10201404662YA (en) Dp2 antagonist and uses thereof
SG10201401145YA (en) Ribbed water spike
EP2437733A4 (en) Sustained release dosage form
GB0906828D0 (en) Reference electrode and combined electrode
PL2208413T3 (en) Square Baler
IL215843A0 (en) Arylsulfonamide ccr3 antagonists
GB0908898D0 (en) Dog excrement capturing tool
GB0905435D0 (en) Building construction device
GB0909824D0 (en) Wedge device
GB0903839D0 (en) Bricklayers easy line
GB0915890D0 (en) Energy capture
TWM365713U (en) Portable disposable toilet
GB0919336D0 (en) Lumenal remodelling device and methods
GB201016125D0 (en) Energy harvesting mat
GB201011617D0 (en) Sustainable energy from waste
GB0917651D0 (en) Improvements in building
GB0909915D0 (en) Improved energy recovery
GB0902128D0 (en) Energy device
HU0900150V0 (en) Energy saving device set
GB201007054D0 (en) Waste compactor